Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATYRNASDAQ:HUMANASDAQ:JNCENASDAQ:VIGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATYRAtyr PHARMA$4.78+6.8%$3.28$1.42▼$4.83$424.99M0.79954,881 shs2.29 million shsHUMAHumacyte$2.62-2.1%$1.71$1.15▼$9.79$405.64M1.643.78 million shs4.08 million shsJNCEJounce Therapeutics$1.88$1.89$0.58▼$5.87$98.94M0.752.46 million shs169,314 shsVIGLVigil Neuroscience$7.92+0.3%$2.79$1.31▼$7.95$369.41M1.9659,155 shs501,789 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATYRAtyr PHARMA0.00%+18.13%+23.06%+34.24%+442,999,900.00%HUMAHumacyte0.00%+5.93%+104.58%-12.42%-64.17%JNCEJounce Therapeutics0.00%0.00%0.00%0.00%0.00%VIGLVigil Neuroscience0.00%-0.13%+186.55%+259.82%+147.80%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATYRAtyr PHARMA2.7796 of 5 stars3.61.00.00.03.43.30.6HUMAHumacyte2.4778 of 5 stars3.51.00.00.03.42.50.6JNCEJounce TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AVIGLVigil Neuroscience3.1464 of 5 stars4.03.00.00.02.32.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATYRAtyr PHARMA 3.14Buy$18.60289.53% UpsideHUMAHumacyte 3.00Buy$11.71347.97% UpsideJNCEJounce Therapeutics 0.00N/AN/AN/AVIGLVigil Neuroscience 2.00Hold$10.8036.45% UpsideCurrent Analyst Ratings BreakdownLatest JNCE, HUMA, VIGL, and ATYR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025VIGLVigil NeuroscienceStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$11.00 ➝ $8.005/27/2025VIGLVigil NeuroscienceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$14.00 ➝ $8.005/23/2025VIGLVigil NeuroscienceMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/22/2025VIGLVigil NeuroscienceJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeHold5/22/2025VIGLVigil NeuroscienceGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Neutral$8.005/22/2025VIGLVigil NeuroscienceCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeMarket Perform5/22/2025VIGLVigil NeuroscienceGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/22/2025VIGLVigil NeuroscienceCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/22/2025VIGLVigil NeuroscienceJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform5/22/2025VIGLVigil NeuroscienceWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$13.00 ➝ $8.005/19/2025ATYRAtyr PHARMAHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.00 ➝ $35.00(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATYRAtyr PHARMA$235K1,808.49N/AN/A$1.54 per share3.10HUMAHumacyte$517K784.60N/AN/A$0.13 per share20.12JNCEJounce Therapeutics$82M1.21N/AN/A$3.54 per share0.53VIGLVigil NeuroscienceN/AN/AN/AN/A$3.24 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATYRAtyr PHARMA-$50.39M-$0.81N/AN/AN/AN/A-79.44%-59.16%8/12/2025 (Estimated)HUMAHumacyte-$110.78M-$0.69N/AN/AN/AN/A-942.81%-93.82%8/12/2025 (Estimated)JNCEJounce Therapeutics-$50.92M-$2.56N/AN/AN/AN/A-30.90%-26.31%N/AVIGLVigil Neuroscience-$82.64M-$2.05N/AN/AN/AN/A-83.89%-65.34%8/12/2025 (Estimated)Latest JNCE, HUMA, VIGL, and ATYR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025HUMAHumacyte-$0.19-$0.10+$0.09$0.28$0.46 million$0.52 million5/7/2025Q1 2025ATYRAtyr PHARMA-$0.19-$0.17+$0.02-$0.17N/AN/A5/7/2025Q1 2025VIGLVigil Neuroscience-$0.53-$0.49+$0.04-$0.49N/AN/A3/28/2025Q4 2024HUMAHumacyte-$0.23-$0.16+$0.07-$0.16$0.64 million$7.23 million3/13/2025Q4 2024ATYRAtyr PHARMA-$0.23-$0.18+$0.05-$0.18$0.02 millionN/A3/13/2025Q4 2024VIGLVigil Neuroscience-$0.49-$0.57-$0.08-$0.57N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATYRAtyr PHARMAN/AN/AN/AN/AN/AHUMAHumacyteN/AN/AN/AN/AN/AJNCEJounce TherapeuticsN/AN/AN/AN/AN/AVIGLVigil NeuroscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATYRAtyr PHARMA0.025.415.41HUMAHumacyteN/A1.101.10JNCEJounce TherapeuticsN/A8.378.37VIGLVigil NeuroscienceN/A3.723.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATYRAtyr PHARMA61.72%HUMAHumacyte44.71%JNCEJounce Therapeutics80.66%VIGLVigil Neuroscience83.64%Insider OwnershipCompanyInsider OwnershipATYRAtyr PHARMA3.70%HUMAHumacyte5.10%JNCEJounce Therapeutics6.92%VIGLVigil Neuroscience18.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATYRAtyr PHARMA5389.00 million80.84 millionOptionableHUMAHumacyte150155.12 million111.76 millionOptionableJNCEJounce Therapeutics13752.63 million48.99 millionOptionableVIGLVigil Neuroscience4046.67 million27.38 millionNot OptionableJNCE, HUMA, VIGL, and ATYR HeadlinesRecent News About These CompaniesShould You Buy Vigil Neuroscience, Inc. (VIGL) After Golden Cross?June 2 at 10:55 AM | zacks.comHC Wainwright Cuts Earnings Estimates for Vigil NeuroscienceMay 31 at 2:45 AM | americanbankingnews.comHC Wainwright Has Bearish Forecast for VIGL FY2026 EarningsMay 30 at 8:42 AM | marketbeat.comVigil Neuroscience (NASDAQ:VIGL) Stock Rating Lowered by Stifel NicolausMay 30 at 2:48 AM | americanbankingnews.comStifel cuts Vigil Neuroscience stock rating, lowers target to $8May 29, 2025 | investing.comVigil Neuroscience (NASDAQ:VIGL) Downgraded by Stifel Nicolaus to HoldMay 29, 2025 | marketbeat.comStifel Downgrades Vigil Neuroscience (VIGL)May 29, 2025 | msn.comVigil Neuroscience (NASDAQ:VIGL) Downgraded by HC Wainwright to HoldMay 29, 2025 | americanbankingnews.comHC Wainwright Reiterates "Neutral" Rating for Vigil Neuroscience (NASDAQ:VIGL)May 28, 2025 | marketbeat.comHC Wainwright & Co. Downgrades Vigil Neuroscience (VIGL)May 28, 2025 | msn.comWoodline Partners LP Has $831,000 Position in Vigil Neuroscience, Inc. (NASDAQ:VIGL)May 28, 2025 | marketbeat.comVigil Neuroscience, Inc. (NASDAQ:VIGL) Receives $15.00 Average Target Price from BrokeragesMay 28, 2025 | americanbankingnews.comWedbush Equities Analysts Reduce Earnings Estimates for VIGLMay 27, 2025 | marketbeat.comQ2 EPS Estimate for Vigil Neuroscience Boosted by AnalystMay 27, 2025 | americanbankingnews.comWilliam Blair Issues Optimistic Outlook for VIGL EarningsMay 27, 2025 | marketbeat.comVigil Neuroscience (NASDAQ:VIGL) Stock Rating Lowered by MizuhoMay 26, 2025 | marketbeat.comVigil Neuroscience (NASDAQ:VIGL) Stock Rating Lowered by GuggenheimMay 26, 2025 | marketbeat.comPoint72 Asset Management L.P. Cuts Stock Holdings in Vigil Neuroscience, Inc. (NASDAQ:VIGL)May 26, 2025 | marketbeat.comMizuho Downgrades Vigil Neuroscience (NASDAQ:VIGL) to HoldMay 26, 2025 | americanbankingnews.comEquities Analysts Issue Forecasts for VIGL FY2027 EarningsMay 25, 2025 | marketbeat.comVigil Neuroscience (NASDAQ:VIGL) Rating Lowered to Hold at Citizens JmpMay 25, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookAMD’s AI-Powered Stock Price Rally Just Shifted GearsBy Thomas Hughes | May 14, 2025View AMD’s AI-Powered Stock Price Rally Just Shifted GearsJNCE, HUMA, VIGL, and ATYR Company DescriptionsAtyr PHARMA NASDAQ:ATYR$4.78 +0.31 (+6.82%) Closing price 03:59 PM EasternExtended Trading$4.77 -0.01 (-0.10%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.Humacyte NASDAQ:HUMA$2.62 -0.06 (-2.06%) Closing price 03:59 PM EasternExtended Trading$2.65 +0.04 (+1.49%) As of 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Jounce Therapeutics NASDAQ:JNCEJounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.Vigil Neuroscience NASDAQ:VIGL$7.92 +0.03 (+0.32%) Closing price 03:59 PM EasternExtended Trading$7.92 +0.01 (+0.13%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Why SoundHound Could Be a Short Squeeze in the Making Why Schwab US Dividend Equity ETF Could Lead the Rotation Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell 5 Reasons Costco Stock Will Hit New Highs This Year Ackman Takes a Swing at Amazon — Should You? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
